News

Recent news about Panacea Venture and select portfolio companies

September 6, 2023

MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer

The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

September 6, 2023

MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer

The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

September 5, 2023

David Topper Joined Inmagene as CFO

September 5, 2023

David Topper Joined Inmagene as CFO

August 23, 2023

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients WARRINGTON, Pa. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on

August 23, 2023

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients WARRINGTON, Pa. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on

August 18, 2023

Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

August 18, 2023

Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

August 17, 2023

Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth

August 17, 2023

Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth